Compare DexCom, Inc. (DXCM) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Verizon Communications Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Verizon Communications Inc trades at $41.65 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 6× DexCom, Inc.'s market cap, and Verizon Communications Inc pays a 6.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Verizon Communications Inc for 109 Days on average.
| DXCM | VZ | |
|---|---|---|
Market Cap | $31.86B | $192.57B |
Volume | 3,607,070 | 20,940,094 |
Sector | Health | Media |
52-Week High | $92.34 | $51.45 |
52-Week Low | $54.84 | $38.40 |
Typical Hold Time | 62 Days | 109 Days |
Enterprise Value | $31.32B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Verizon (VZ) trades at $46.35, up 1.27% today, with a bearish technical signal despite recent earnings beats. The stock shows stable revenue around $138B annually with strong cash flow generation of $37.1B from operations in 2025. Valuation metrics appear reasonable with P/E of 12.07 and EV/EBITDA of 7.9, while the company maintains a solid dividend yield supported by consistent cash flows.
Outlook remains stable with moderate growth prospects amid competitive telecom landscape. Investment appeal centers on dividend reliability and defensive positioning, though technical weakness and modest revenue growth present near-term challenges. Risks include intense competition and capital expenditure requirements for network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
